Capricor Therapeutics (CAPR) Common Equity (2010 - 2026)

Capricor Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $278.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 118.34% year-over-year to $278.7 million; the TTM figure through Mar 2026 stood at $278.7 million (up 118.34% YoY), while the FY2025 annual figure was $305.8 million, up 110.22% from the prior year.
• Common Equity for Q1 2026 stood at $278.7 million, down from $305.8 million in the prior quarter.
• The five-year high for Common Equity was $305.8 million in Q4 2025, with the low at -$1.8 million in Q3 2023.
• The 5-year median for Common Equity is $22.6 million (2023), against an average of $73.2 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 111.59% in 2023, then jumped 3918.69% in 2024.
• Capricor Therapeutics' Common Equity stood at $11.8 million in 2022, then jumped by 91.76% to $22.6 million in 2023, then jumped by 543.6% to $145.5 million in 2024, then surged by 110.22% to $305.8 million in 2025, then dropped by 8.86% to $278.7 million in 2026.
• Business Quant data shows CAPR's Common Equity at $278.7 million in Q1 2026, $305.8 million in Q4 2025, and $83.9 million in Q3 2025.